Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reissued an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Canaccord Genuity Group decreased their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Finally, Wells Fargo & Company decreased their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VTYX. Palumbo Wealth Management LLC bought a new position in Ventyx Biosciences in the third quarter valued at about $26,000. China Universal Asset Management Co. Ltd. grew its position in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares during the last quarter. SG Americas Securities LLC bought a new position in Ventyx Biosciences in the second quarter valued at about $32,000. Intech Investment Management LLC bought a new position in Ventyx Biosciences in the third quarter valued at about $42,000. Finally, The Manufacturers Life Insurance Company grew its position in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

VTYX opened at $1.73 on Friday. Ventyx Biosciences has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The company has a market capitalization of $122.33 million, a P/E ratio of -0.73 and a beta of 0.37. The stock has a fifty day moving average of $2.20 and a 200-day moving average of $2.70.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.